Search

Displaying results 2621 - 2630 of 10000 in total
  1. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]

  2. Drug

    Collagenase clostridium histolyticum

    go.drugbank.com/drugs/DB00048
    ApprovedInvestigational

    [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.

  3. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257325,A257335,L45310] Compared to [irbesartan], sparsentan reduces proteinuria to a greater extent.

  4. Drug

    Novobiocin

    go.drugbank.com/drugs/DB01051
    ApprovedInvestigationalVet approvedWithdrawn

    In 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.[L44062,L43942]

  5. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].

  6. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).

    Synonyms: BRX-220 FREE BASE
  7. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    based on favorable results obtained from Pfizer’s Elevate UC Phase III registrational program, consisting of the Elevate UC 52 and Elevate UC 12 clinical trials, that investigates the efficacy of a 2-mg

  8. Drug

    Acetate

    go.drugbank.com/drugs/DB14511
    Investigational

    Mixtures: PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 2000 ML, NUTRIFLEX LIPID PLUS INFUZYONLUK EMULSIYON, 2500 ML
  9. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.

  10. Drug

    Potassium guaiacolsulfonate

    go.drugbank.com/drugs/DB13735
    ApprovedWithdrawn

    Guaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.

    Mixtures: ARTU 100 ML SURUP, ANTIBEKSIN SURUP, 100 ML